Laboratory research material

Tesamorelin 10mg

£39.99

Tesamorelin 10mg research peptide UK is the advanced-format full-length 44-amino acid GHRH analogue for established UK laboratory programmes requiring multi-arm or longitudinal GHRH receptor engagement studies. Janoshik report published for a tested batch. Same working-day UK dispatch on in-stock orders before 3pm (Mon–Fri). Research use only.

Research guides: What Is Tesamorelin? · Tesamorelin 10mg research guide

  • Same working-day dispatch on in-stock orders before 3pm, Mon–Fri
  • Royal Mail Tracked 24, free UK delivery on orders of £50 or more
  • Certificates of analysis published on our CoA page
  • Laboratory research use only; 18+ to purchase
Key Features
  • Form: Lyophilized peptide powder
  • Quantity: 1 vial (10mg)
  • Intended Use: Research purposes only

Safety Information: Not intended for human or veterinary use. Use appropriate laboratory safety procedures when handling.

TESAMORELIN 10mg should only be used in laboratory settings by qualified personnel.

Ensure all experimental procedures comply with local and institutional regulations.

This peptide is supplied for research and scientific study purposes only

Tesamorelin 10mg:
View Janoshik report #125394 (tested sample: Tesamorelin 10mg)

This report covers one tested sample. It does not establish that current stock comes from the same batch.

Product Details

Tesamorelin 10mg Research Peptide UK

Tesamorelin 10mg is the larger-format version of Tesamorelin 5mg: the same full-length (44-amino-acid) GHRH analogue with an N-terminal trans-3-hexenoic acid modification. Published reference properties, not analytical results for the supplied vial: C221H366N72O67S, approximately 5,136 g/mol (PubChem CID 16137828; CAS 218949-48-5). For background, see What Is Tesamorelin?.

At a glance

  • Quantity10mg
  • FormatLyophilized peptide powder
  • Intended useResearch use only

Full Research Information

The tesamorelin 10mg research peptide format is appropriate when the pilot phase has validated the experimental design using the 5mg format, and the full research programme now requires consistent compound conditions across multiple time points or treatment arms. Where batch-to-batch variability matters to a longitudinal design, record the batch reference of the material received. For first-time tesamorelin research and full mechanism detail, see the tesamorelin 5mg research guide and the tesamorelin 10mg research guide on the Ascend Peptides UK blog.

Tesamorelin 10mg is particularly suited to multi-analogue GHRH comparison studies run at the scale that parallel arms require. The complete three-analogue comparison — Tesamorelin 10mg (full-length 44 AA), CJC-1295 Without DAC 10mg (modified 29 AA, DPP-IV resistant), and Sermorelin 2mg (unmodified 29 AA) — provides a comprehensive GHRH structural toolkit. These three compounds differ in sequence length and in their protection against DPP-IV cleavage, allowing comparative evaluation of sequence length and enzymatic stability within experimental models.

For GHRP complement in combined pulsatile GH protocols alongside tesamorelin, Ipamorelin 10mg provides the GHS-R1a pathway activation that is mechanistically distinct from GHRHR activation. For downstream IGF-1 axis research alongside GH axis stimulation studies, IGF-1 LR3 1mg provides the growth factor research tool.

Evidence status: tesamorelin is the active substance of Egrifta, approved in the United States in 2010 to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, on the basis of randomised controlled trials (Falutz et al., N Engl J Med, 2007). The EU marketing-authorisation application was withdrawn in 2012 before a final opinion. These clinical data concern a licensed formulation and patient population; they do not describe or verify the research material supplied here.

A published Janoshik report covers a tested sample of Tesamorelin 10mg; its batch reference, measured content and purity are listed with the report on the Certificates of Analysis page, under the laboratory’s reported assessment. Measured content and purity are separate results, and neither describes every vial in current stock. The report does not state the analytical method and does not separately report a mass-spectrometry identity result, the salt form, or sterility or endotoxin testing. View the Tesamorelin 10mg report on the Certificates of Analysis page.

Storage requirements for Tesamorelin are currently being verified with the manufacturer. Ascend Peptides UK does not publish reconstitution, solvent or in-use instructions; these are decisions for your own validated laboratory protocol.

WADA Status

Prohibited at all times.

Disclaimer

For in-vitro research only. Not an MHRA-licensed medicine.

More Research Materials

Other laboratory research materials supplied by Ascend Peptides UK.

Acetic Acid 10ml research solvent vial

Acetic Acid 10ml

Spend £75 and get a FREE BACTERIOSTATIC WATER 10ML

Bacteriostatic Water 10ml research solvent vial

Bacteriostatic Water 10ml

Spend £75 and get a FREE BACTERIOSTATIC WATER 10ML

MOTS-C 40mg UK research peptide vial

MOTS-C 40mg

Spend £75 and get a FREE BACTERIOSTATIC WATER 10ML

MOTS-C 10mg UK research peptide vial

MOTS-C 10mg

Spend £75 and get a FREE BACTERIOSTATIC WATER 10ML